Campbell & CO Investment Adviser LLC Purchases Shares of 30,210 TG Therapeutics, Inc. $TGTX

Campbell & CO Investment Adviser LLC acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 30,210 shares of the biopharmaceutical company’s stock, valued at approximately $1,091,000.

Other large investors have also recently made changes to their positions in the company. State Street Corp grew its holdings in TG Therapeutics by 2.5% during the 2nd quarter. State Street Corp now owns 7,618,238 shares of the biopharmaceutical company’s stock worth $274,180,000 after acquiring an additional 184,339 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of TG Therapeutics by 6.3% during the 2nd quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company’s stock worth $126,033,000 after purchasing an additional 207,890 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of TG Therapeutics by 21.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock worth $75,683,000 after purchasing an additional 345,059 shares in the last quarter. Hood River Capital Management LLC grew its stake in shares of TG Therapeutics by 0.7% during the second quarter. Hood River Capital Management LLC now owns 1,567,506 shares of the biopharmaceutical company’s stock worth $56,415,000 after purchasing an additional 11,018 shares in the last quarter. Finally, Eventide Asset Management LLC increased its holdings in TG Therapeutics by 32.8% in the second quarter. Eventide Asset Management LLC now owns 954,531 shares of the biopharmaceutical company’s stock valued at $34,354,000 after buying an additional 235,717 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Down 0.5%

Shares of NASDAQ:TGTX opened at $30.57 on Monday. TG Therapeutics, Inc. has a 1-year low of $25.28 and a 1-year high of $46.48. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.82 and a quick ratio of 2.89. The stock has a market cap of $4.85 billion, a P/E ratio of 11.00 and a beta of 1.86. The firm has a fifty day moving average price of $30.77 and a 200 day moving average price of $32.48.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The company had revenue of $161.71 million for the quarter, compared to analyst estimates of $152.12 million. During the same period in the previous year, the business posted $0.02 earnings per share. TG Therapeutics’s quarterly revenue was up 92.7% on a year-over-year basis. Sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Key Headlines Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Seeking Alpha published an upgrade/positive piece that highlights accelerating commercial momentum and investor “exit velocity,” supporting a more bullish growth narrative for TG Therapeutics. TG Therapeutics: The ‘Exit Velocity’ You Can’t Ignore (Rating Upgrade)
• Positive Sentiment: Media reported that Goldman Sachs sees substantial upside (~32% rally potential) as Briumvi sales accelerate, which supports a bullish case for continued revenue and earnings upside. TG Therapeutics stock pops as Briumvi boom reignites bull case: Goldman Sachs sees room for 32% rally
• Positive Sentiment: HC Wainwright raised its Q4 2025 EPS estimate to $0.27 (from $0.20) and keeps a “Buy” rating with a $60 target — a clear near‑term analyst endorsement that can support upside. MarketBeat TGTX analyst note
• Positive Sentiment: HC Wainwright also raised FY2025 EPS to $2.89 (from $2.83), reflecting stronger near‑term earnings expectations tied to current product momentum. MarketBeat TGTX analyst note
• Neutral Sentiment: HC Wainwright published a set of long‑range forecasts (FY2026–FY2030, including FY2030 EPS of $3.96). These long‑horizon numbers frame upside potential but are model‑dependent and less immediately market‑moving. MarketBeat TGTX analyst note
• Negative Sentiment: Bank of America Securities initiated/maintained a “Sell” on TGTX, which is directly bearish and likely pressured the stock amid mixed optimism elsewhere. TG Therapeutics (TGTX) Receives a Sell from Bank of America Securities
• Negative Sentiment: HC Wainwright trimmed several mid‑to‑longer‑term estimates (Q4 2026, FY2026–FY2029, FY2028–FY2029 down slightly), signaling some moderation in the firm’s prior growth assumptions and reducing upside in those years despite the persistent $60 target. MarketBeat TGTX analyst note

Analysts Set New Price Targets

A number of analysts have issued reports on the company. The Goldman Sachs Group lifted their price target on TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a report on Thursday. HC Wainwright began coverage on TG Therapeutics in a research note on Monday, October 6th. They set a “buy” rating and a $60.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of TG Therapeutics in a research note on Wednesday. Wall Street Zen raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, December 14th. Finally, B. Riley upgraded shares of TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $50.75.

Insiders Place Their Bets

In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $32.57, for a total value of $162,850.00. Following the transaction, the director directly owned 223,816 shares in the company, valued at approximately $7,289,687.12. This trade represents a 2.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 10.64% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.